$775.8 M

ABEO Mkt cap, 22-Jun-2018

$2.6 M

Abeona Therapeutics Revenue Q1, 2018
Abeona Therapeutics Net income (Q1, 2018)-8.5 M
Abeona Therapeutics EBIT (Q1, 2018)-8.6 M
Abeona Therapeutics Cash, 31-Mar-2018132 M

Abeona Therapeutics Financials

Abeona Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2 m925 k1 m889 k837 k

Revenue growth, %

(55%)12%(15%)

R&D expense

10.7 m17 m

General and administrative expense

13.3 m10.9 m

Operating expense total

23.9 m28.7 m

Depreciation and amortization

741 k

EBIT

(3.8 m)(3.1 m)(18.5 m)(23.9 m)(27.8 m)

EBIT margin, %

(186%)(338%)(1783%)(2686%)(3326%)

Net Income

4.4 m(26.8 m)(14.5 m)(21.9 m)(27.3 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

189 k208 k247 k236 k258 k285 k235 k214 k184 k186 k217 k219 k2.6 m

R&D expense

236 k72 k81 k73 k453 k1.6 m1.9 m3 m2.7 m2.2 m5.8 m3.3 m8.2 m

General and administrative expense

642 k733 k868 k795 k1.7 m4.7 m4.4 m3.7 m2.4 m3 m2.6 m2.2 m2.9 m

Operating expense total

885 k805 k950 k869 k2.3 m6.4 m6.4 m6.9 m5.4 m5.5 m8.7 m5.6 m11.2 m

Depreciation and amortization

138 k174 k

EBIT

(696 k)(597 k)(703 k)(633 k)(2 m)(6.2 m)(6.2 m)(6.7 m)(5.2 m)(5.3 m)(8.4 m)(5.4 m)(8.6 m)

EBIT margin, %

(368%)(287%)(285%)(268%)(776%)(2163%)(2621%)(3138%)(2812%)(2841%)(3889%)(2448%)(332%)

Net Income

(157 k)(128 k)(12.5 m)(1.5 m)(2 m)(6.1 m)(5.5 m)(6.7 m)(2.6 m)(5.2 m)(8.3 m)(5.3 m)(8.5 m)

Abeona Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

424 k11.5 m40.1 m69.1 m137.8 m

Accounts Receivable

107 k

Inventories

77 k315 k155 k

Current Assets

575 k11.6 m40.6 m69.4 m140.6 m

PP&E

6 k4 k350 k721 k1.4 m

Goodwill

32.5 m32.5 m

Total Assets

613 k16.6 m80.1 m111.1 m178.8 m

Accounts Payable

863 k1.9 m875 k3.7 m2.4 m

Current Liabilities

9 m2.9 m1.5 m8.3 m5.6 m

Total Liabilities

12 m8.7 m

Additional Paid-in Capital

251.4 m300.7 m378 m431.2 m529.4 m

Retained Earnings

(266.4 m)(296.1 m)(310.6 m)(332.5 m)(359.8 m)

Total Equity

(14.8 m)4.8 m67.7 m99.1 m170.1 m

Financial Leverage

0 x3.4 x1.2 x1.1 x1.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

899 k299 k55 k165 k7.9 m43.3 m37.4 m34.3 m31.2 m63.2 m58.3 m56.5 m132 m

Accounts Receivable

64 k

Inventories

1.8 m

Current Assets

1 m440 k203 k244 k8.2 m43.7 m37.8 m34.6 m31.9 m63.8 m59.3 m58.4 m134.2 m

PP&E

6 k6 k5 k4 k11 k87 k548 k639 k748 k748 k709 k730 k4.8 m

Goodwill

39 m32.5 m32.5 m32.5 m32.5 m32.5 m32.5 m32.5 m

Total Assets

1.1 m478 k240 k280 k13.1 m89.5 m77.4 m74.2 m73.8 m105.3 m96.7 m95.7 m175.7 m

Accounts Payable

706 k1.1 m1.3 m1.6 m638 k968 k1 m2.1 m1.9 m1.5 m3.6 m2 m5.9 m

Dividends Payable

5.9 m7.5 m8.4 m9.3 m

Current Liabilities

8 m10 m11.2 m12.6 m1.2 m1.6 m7.6 m8.7 m6.5 m6.1 m4.2 m2.6 m6.5 m

Total Liabilities

14.3 m16 m28.6 m30.6 m10 m16.5 m11.8 m12.7 m10.3 m9.6 m7.6 m5.9 m6.5 m

Additional Paid-in Capital

251.2 m251.5 m252.6 m253.1 m301 m381 m381.5 m384 m388.6 m433 m434.7 m440.8 m533.3 m

Retained Earnings

(264.7 m)(267.3 m)(281.2 m)(283.4 m)(298.1 m)(308.3 m)(316.1 m)(322.8 m)(325.5 m)(337.7 m)(346 m)(351.3 m)(364.6 m)

Total Equity

(13.2 m)(15.5 m)(28.4 m)(30.4 m)3.2 m73.1 m65.7 m61.5 m63.5 m95.7 m89.1 m89.9 m169.2 m

Financial Leverage

-0.1 x0 x0 x0 x4.2 x1.2 x1.2 x1.2 x1.2 x1.1 x1.1 x1.1 x1 x

Abeona Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

4.4 m(26.8 m)(14.5 m)(21.9 m)(27.3 m)

Depreciation and Amortization

3 k11 k551 k825 k741 k

Accounts Receivable

17 k

Inventories

174 k77 k(287 k)160 k

Accounts Payable

(1.2 m)33 k(1.2 m)2.8 m(1.3 m)

Cash From Operating Activities

1 k(1.6 m)(10.4 m)(13 m)(22.9 m)

Cash From Investing Activities

(2 k)3.4 m(519 k)

Cash From Financing Activities

29 k12.7 m35.7 m42.5 m92.4 m

Interest Paid

7 k7 k6 k8 k

Free Cash Flow

(1 k)(1.6 m)(10.7 m)(13.5 m)(23.8 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(157 k)(128 k)(12.5 m)(1.5 m)(2 m)(12.2 m)(5.5 m)(12.2 m)(14.9 m)(5.2 m)(8.5 m)

Depreciation and Amortization

1 k1 k118 k401 k174 k355 k577 k250 k174 k

Accounts Receivable

43 k

Accounts Payable

1.1 m1.3 m1.6 m638 k(1.1 m)1 m1.2 m1 m1.5 m3.5 m

Cash From Operating Activities

(7.5 m)(5.6 m)(9.6 m)(4.1 m)

Cash From Investing Activities

3.7 m(353 k)(501 k)(3.5 m)

Cash From Financing Activities

35.7 m150 k1.2 m1.8 m

Interest Paid

3 k

Free Cash Flow

(7.6 m)(6 m)(10.1 m)(7.6 m)

Abeona Therapeutics Ratios

USDY, 2018

Revenue/Employee

136.7 k

Financial Leverage

1 x
Report incorrect company information